Y-mAbs Reports European Medicines Agency’s Committee For Orphan Medicinal Products Recommended Granting Orphan Medicinal Product Designation In EU For Medulloblastoma Treatment
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (NASDAQ:YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based